- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

In the aggregate, the maximum milestone payments to be received from the collaborative partner.

+ References

No definition available.

+ Details

Name:	vygr_CollaborativeArrangementAggregateMaximumMilestonePaymentsToBeReceivedFromCollaborativePartner
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum potential in-kind services to be provided by a collaborative partner.

+ References

No definition available.

+ Details

Name:	vygr_CollaborativeArrangementInkindServicesToBeProvidedByCollaborativePartnerMaximumPotential
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The non-redeemable upfront fee received by the reporting entity from the collaborative partner.

+ References

No definition available.

+ Details

Name:	vygr_CollaborativeArrangementNonredeemableUpFrontFeeReceived
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of anniversary date of the Future Program nomination by the counterparty that triggers a reduction in the milestone or royalty payments to be made by the collaborative partner.

+ References

No definition available.

+ Details

Name:	vygr_CollaborativeArrangementNumberOfAnniversaryDateOfFutureProgramNominationByCounterPartyThatTriggersReductionInMilestoneOrRoyaltyPaymentsMadeByCollaborativePartner
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Option exercise payment required from collaborative partner for each program specified.

+ References

No definition available.

+ Details

Name:	vygr_CollaborativeArrangementOptionExercisePaymentRequiredFromCollaborativePartnerForEachProgramSpecified
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Per milestone, the maximum milestone payments to be received from the collaborative partner.

+ References

No definition available.

+ Details

Name:	vygr_CollaborativeArrangementPerMilestoneMaximumMilestonePaymentsToBeReceivedFromCollaborativePartner
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of collaborative arrangement related milestone payments that are no longer receivable.

+ References

No definition available.

+ Details

Name:	vygr_CollaborativeArrangementRelatedMilestonePaymentsThatAreNoLongerReceivable
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate fair value of temporary equity.

+ References

No definition available.

+ Details

Name:	vygr_TemporaryEquityFairValue
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The premium over the aggregate fair value of the temporary equity.

+ References

No definition available.

+ Details

Name:	vygr_TemporaryEquityPremium
Namespace Prefix:	vygr_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of new stock classified as temporary equity issued during the period upon exchange of convertible debt.

+ References

No definition available.

+ Details

Name:	vygr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssuesUponExchangeOfConvertibleDebt
Namespace Prefix:	vygr_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	vygr_MilestoneAchievementAxis=vygr_RegulatoryApprovalMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=vygr_GenzymeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vygr_MilestoneAchievementAxis=vygr_CommercialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=vygr_ParkinsonProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	vygr_MilestoneAchievementAxis=vygr_RegulatoryAndCommercialMilestoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=vygr_SpinalMuscularAtrophyProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=vygr_SplitTerritoryProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=vygr_RedeemableConvertiblePreferredStockSeriesBMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and contingencies - Significant Agreements - (Details) - Sanofi Genzyme - USD ($) $ in Millions	1 Months Ended
	Oct. 31, 2017	Feb. 28, 2015
Regulatory approval milestone
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate maximum milestone payments to be received from collaborative partner	$ 220.0
Regulatory approval milestone \| Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Per Milestone, maximum milestone payments to be received from collaborative partner	40.0
Regulatory approval milestone \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Per Milestone, maximum milestone payments to be received from collaborative partner	50.0
Commercial Milestone
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Aggregate maximum milestone payments to be received from collaborative partner	320.0
Commercial Milestone \| Minimum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Per Milestone, maximum milestone payments to be received from collaborative partner	50.0
Commercial Milestone \| Maximum
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Per Milestone, maximum milestone payments to be received from collaborative partner	$ 100.0
Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment received		$ 65.0
Premium over fair value on temporary equity issued		5.0
Amount of reduction in milestone or royalty payments to be made by collaborative partner for each program specified		10.0
Per Milestone, maximum milestone payments to be received from collaborative partner		540.0
Parkinson's Program \| Regulatory and commercial milestone
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments no longer receivable		105.0
Spinal Muscular Atrophy Program \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum potential in-kind services to be provided by collaborative partner		5.0
Option exercise payment required from collaborative partner for each program specified		30.0
Split Territory Program \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Option exercise payment required from collaborative partner for each program specified		20.0
Redeemable Convertible Preferred Stock Series B \| Collaborative Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Non-refundable upfront payment received		$ 30.0
Temporary equity issued (in shares)		10,000,000
Fair value of temporary equity issued		$ 25.0